"that October, the FDA issued a complete response letter for the same candidate in a different indication, pediatric acute graft-versus-host disease, over issues with trial design. Mesoblast had submitted its application on the basis of one single-arm, open-label study rather than a randomized trial, even though the drug demonstrated a statistically significant benefit in its primary endpoint against the historical control rate."
have to be remember..... well atleast the FDA should they advised and agreed with the single arm. and as said by many here ...the FDA changed the goal posts after admin stuff ups
"that October, the FDA issued a complete response letter for the...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |